METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 Russian patent published in 2022 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine and molecular biology, to biotechnology. Substance of the invention consists in using a set of reagents for competition solid-phase enzyme immunoassay to determine the neutralising antibodies blocking the interaction of the virus with the extracellular domain ACE2 of the receptors of human target cells in the serum or plasma of convalescents and patients with past cases of COVID-19, as well as people vaccinated against SARS-CoV-2. The tested biological sample is incubated on an immunosorbent containing antigenic determinants of the RBDS1 domain of the SARS-CoV-2 protein, and then the presence of neutralising properties is controlled in the attached antibodies by the ability thereof to bind to proteins of the ACE2 receptor complex of the human cells.

EFFECT: expanded range of test systems for serological diagnosis of COVID-19 for the purpose of detecting neutralising antibodies in the serum or plasma of people with past cases of COVID-19 or vaccinated against SARS-CoV-2 in order to determine the susceptibility thereof to infection with said coronavirus.

11 cl, 3 dwg, 3 tbl